Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. CPRX
  6. >
  7. Valuation
stocks logo

CPRX Valuation

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)

CPRX Relative Valuation

CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPRX is overvalued; if below, it's undervalued.

Historical Valuation

Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.36 is considered Fairly compared with the five-year average of 13.69. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 13.82 to 23.95 according to relative valuation methord.
Relative Value
Fair Zone
13.82-23.95
Current Price:21.81
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.32
P/B
Median3y
4.33
Median5y
3.82
10.04
FCF Yield
Median3y
3.62
Median5y
6.03

Competitors Valuation Multiple

The average P/S ratio for CPRX's competitors is 46.16, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.79, which is -89.61% above the industry average. Given its robust revenue growth of 43.56%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap

People Also Watch

FAQ

arrow icon

Is Catalyst Pharmaceuticals Inc (CPRX) currently overvalued or undervalued?

Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.36 is considered Fairly compared with the five-year average of 13.69. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 13.82 to 23.95 according to relative valuation methord.
arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX) fair value?

CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 13.82 to 23.95 according to relative valuation methord.
arrow icon

How does CPRX's valuation metrics compare to the industry average?

The average P/S ratio for CPRX's competitors is 46.16, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.79, which is -89.61% above the industry average. Given its robust revenue growth of 43.56%, this premium appears sustainable.
arrow icon

What is the current P/B ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?

As of Jul 13 2025, Catalyst Pharmaceuticals Inc (CPRX) has a P/B ratio of 3.32. This indicates that the market values CPRX at 3.32 times its book value.
arrow icon

What is the current FCF Yield for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?

As of Jul 13 2025, Catalyst Pharmaceuticals Inc (CPRX) has a FCF Yield of 10.04%. This means that for every dollar of Catalyst Pharmaceuticals Inc’s market capitalization, the company generates 10.04 cents in free cash flow.
arrow icon

What is the current Forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?

As of Jul 13 2025, Catalyst Pharmaceuticals Inc (CPRX) has a Forward P/E ratio of 15.36. This means the market is willing to pay $15.36 for every dollar of Catalyst Pharmaceuticals Inc’s expected earnings over the next 12 months.
arrow icon

What is the current Forward P/S ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jul 13 2025?

As of Jul 13 2025, Catalyst Pharmaceuticals Inc (CPRX) has a Forward P/S ratio of 4.79. This means the market is valuing CPRX at $4.79 for every dollar of expected revenue over the next 12 months.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free